Background: The prospective multicentre observational INVIDIa-2 study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving immune checkpoint inhibitors (ICI). In this secondary analysis of the original trial, we aimed to assess the outcomes of patients to immunotherapy based on vaccine administration. Methods: The original study enrolled patients with advanced solid tumours receiving ICI at 82 Italian Oncology Units from Oct 1, 2019, to Jan 31, 2020. The trial's primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020, the results of which were reported previously. Secondary endpoints (data cut-off Jan 31, 2022) included the outcomes of patients to immunotherapy based on vaccine administration, for which the final results are reported herein. A propensity score matching by age, sex, performance status, primary tumour site, comorbidities, and smoking habits was planned for the present analysis. Only patients with available data for these variables were included. The outcomes of interest were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease-control rate (DCR). Findings: The original study population consisted of 1188 evaluable patients. After a propensity score matching, 1004 patients were considered (502 vaccinated and 502 unvaccinated), and 986 of them were evaluable for overall survival (OS). At the median follow-up of 20 months, the influenza vaccination demonstrated a favourable impact on the outcome receiving ICI in terms of median OS [27.0 months (CI 19.5-34.6) in vaccinated vs. 20.9 months (16.6-25.2) in unvaccinated, p = 0.003], median progression-free survival [12.5 months (CI 10.4-14.6) vs. 9.6 months (CI 7.9-11.4), p = 0.049], and disease-control rate (74.7% vs. 66.5%, p = 0.005). The multivariable analyses confirmed the favourable impact of influenza vaccination in terms of OS (HR 0.75, 95% C.I. 0.62-0.92; p = 0.005) and DCR (OR 1.47, 95% C.I. 1.11-1.96; p = 0.007). Interpretation: The INVIDIa-2 study results suggest a favourable immunological impact of influenza vaccination on the outcome of cancer patients receiving ICI immunotherapy, further encouraging the vaccine recommendation in this population and supporting translational investigations about the possible synergy between antiviral and antitumour immunity. Funding: The Federation of Italian Cooperative Oncology Groups (FICOG), Roche S.p.A., and Seqirus.

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study / Bersanelli, Melissa; Verzoni, Elena; Cortellini, Alessio; Giusti, Raffaele; Calvetti, Lorenzo; Ermacora, Paola; Di Napoli, Marilena; Catino, Annamaria; Guadalupi, Valentina; Guaitoli, Giorgia; Scotti, Vieri; Mazzoni, Francesca; Veccia, Antonello; Guglielmini, Pamela Francesca; Perrone, Fabiana; Maruzzo, Marco; Rossi, Ernesto; Casadei, Chiara; Montesarchio, Vincenzo; Grossi, Francesco; Rizzo, Mimma; Travagliato Liboria, Maria Grazia; Mencoboni, Manlio; Zustovich, Fable; Fratino, Lucia; Accettura, Caterina; Cinieri, Saverio; Camerini, Andrea; Sorarù, Mariella; Zucali, Paolo Andrea; Ricciardi, Serena; Russo, Antonio; Negrini, Giorgia; Banzi, Maria Chiara; Lacidogna, Gaetano; Fornarini, Giuseppe; Laera, Letizia; Mucciarini, Claudia; Santoni, Matteo; Mosillo, Claudia; Bonetti, Andrea; Longo, Lucia; Sartori, Donata; Baldini, Editta; Guida, Michele; Iannopollo, Mauro; Bordonaro, Roberto; Morelli, Maria Francesca; Tagliaferri, Pierosandro; Spada, Massimiliano; Ceribelli, Anna; Silva, Rosa Rita; Nolè, Franco; Beretta, Giordano; Giovanis, Petros; Santini, Daniele; Luzi Fedeli, Stefano; Nanni, Oriana; Maiello, Evaristo; Labianca, Roberto; Pinto, Carmine; Clemente, Alberto; Tognetto, Michele; De Giorgi, Ugo; Pignata, Sandro; Di Maio, Massimo; Buti, Sebastiano; Giannarelli, Diana. - In: ECLINICALMEDICINE. - ISSN 2589-5370. - 61:(2023), p. 102044. [10.1016/j.eclinm.2023.102044]

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study

Bersanelli, Melissa;Buti, Sebastiano
Conceptualization
;
2023-01-01

Abstract

Background: The prospective multicentre observational INVIDIa-2 study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving immune checkpoint inhibitors (ICI). In this secondary analysis of the original trial, we aimed to assess the outcomes of patients to immunotherapy based on vaccine administration. Methods: The original study enrolled patients with advanced solid tumours receiving ICI at 82 Italian Oncology Units from Oct 1, 2019, to Jan 31, 2020. The trial's primary endpoint was the time-adjusted incidence of influenza-like illness (ILI) until April 30, 2020, the results of which were reported previously. Secondary endpoints (data cut-off Jan 31, 2022) included the outcomes of patients to immunotherapy based on vaccine administration, for which the final results are reported herein. A propensity score matching by age, sex, performance status, primary tumour site, comorbidities, and smoking habits was planned for the present analysis. Only patients with available data for these variables were included. The outcomes of interest were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease-control rate (DCR). Findings: The original study population consisted of 1188 evaluable patients. After a propensity score matching, 1004 patients were considered (502 vaccinated and 502 unvaccinated), and 986 of them were evaluable for overall survival (OS). At the median follow-up of 20 months, the influenza vaccination demonstrated a favourable impact on the outcome receiving ICI in terms of median OS [27.0 months (CI 19.5-34.6) in vaccinated vs. 20.9 months (16.6-25.2) in unvaccinated, p = 0.003], median progression-free survival [12.5 months (CI 10.4-14.6) vs. 9.6 months (CI 7.9-11.4), p = 0.049], and disease-control rate (74.7% vs. 66.5%, p = 0.005). The multivariable analyses confirmed the favourable impact of influenza vaccination in terms of OS (HR 0.75, 95% C.I. 0.62-0.92; p = 0.005) and DCR (OR 1.47, 95% C.I. 1.11-1.96; p = 0.007). Interpretation: The INVIDIa-2 study results suggest a favourable immunological impact of influenza vaccination on the outcome of cancer patients receiving ICI immunotherapy, further encouraging the vaccine recommendation in this population and supporting translational investigations about the possible synergy between antiviral and antitumour immunity. Funding: The Federation of Italian Cooperative Oncology Groups (FICOG), Roche S.p.A., and Seqirus.
2023
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study / Bersanelli, Melissa; Verzoni, Elena; Cortellini, Alessio; Giusti, Raffaele; Calvetti, Lorenzo; Ermacora, Paola; Di Napoli, Marilena; Catino, Annamaria; Guadalupi, Valentina; Guaitoli, Giorgia; Scotti, Vieri; Mazzoni, Francesca; Veccia, Antonello; Guglielmini, Pamela Francesca; Perrone, Fabiana; Maruzzo, Marco; Rossi, Ernesto; Casadei, Chiara; Montesarchio, Vincenzo; Grossi, Francesco; Rizzo, Mimma; Travagliato Liboria, Maria Grazia; Mencoboni, Manlio; Zustovich, Fable; Fratino, Lucia; Accettura, Caterina; Cinieri, Saverio; Camerini, Andrea; Sorarù, Mariella; Zucali, Paolo Andrea; Ricciardi, Serena; Russo, Antonio; Negrini, Giorgia; Banzi, Maria Chiara; Lacidogna, Gaetano; Fornarini, Giuseppe; Laera, Letizia; Mucciarini, Claudia; Santoni, Matteo; Mosillo, Claudia; Bonetti, Andrea; Longo, Lucia; Sartori, Donata; Baldini, Editta; Guida, Michele; Iannopollo, Mauro; Bordonaro, Roberto; Morelli, Maria Francesca; Tagliaferri, Pierosandro; Spada, Massimiliano; Ceribelli, Anna; Silva, Rosa Rita; Nolè, Franco; Beretta, Giordano; Giovanis, Petros; Santini, Daniele; Luzi Fedeli, Stefano; Nanni, Oriana; Maiello, Evaristo; Labianca, Roberto; Pinto, Carmine; Clemente, Alberto; Tognetto, Michele; De Giorgi, Ugo; Pignata, Sandro; Di Maio, Massimo; Buti, Sebastiano; Giannarelli, Diana. - In: ECLINICALMEDICINE. - ISSN 2589-5370. - 61:(2023), p. 102044. [10.1016/j.eclinm.2023.102044]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2951933
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact